Ethanol → (4-{[5-Nitro-2-(3-piperidin-1-yl-benzylamino)-pyrimidin-4-ylamino]-methyl}-cyclohexyl)-carbamic acid tert-butyl ester
反応式
[C:1]([O:5][C:6](=[O:26])[NH:7][C@H:8]1[CH2:13][CH2:12][C@H:11]([CH2:14][NH:15][C:16]2[C:21]([N+:22]([O-:24])=[O:23])=[CH:20][N:19]=[C:18](Cl)[N:17]=2)[CH2:10][CH2:9]1)([CH3:4])([CH3:3])[CH3:2].CCN(CC)CC.[N:34]1([C:40]2[CH:41]=[C:42]([CH:45]=[CH:46][CH:47]=2)[CH2:43][NH2:44])[CH2:39][CH2:38][CH2:37][CH2:36][CH2:35]1.CCO>C(Cl)Cl.CC(N(C)C)=O>[C:1]([O:5][C:6](=[O:26])[NH:7][CH:8]1[CH2:13][CH2:12][CH:11]([CH2:14][NH:15][C:16]2[C:21]([N+:22]([O-:24])=[O:23])=[CH:20][N:19]=[C:18]([NH:44][CH2:43][C:42]3[CH:45]=[CH:46][CH:47]=[C:40]([N:34]4[CH2:39][CH2:38][CH2:37][CH2:36][CH2:35]4)[CH:41]=3)[N:17]=2)[CH2:10][CH2:9]1)([CH3:4])([CH3:3])[CH3:2]参加物
7
反応物 4
生成物 1
試薬・触媒・溶媒 2
実験手順
{trans-4-[(2-Chloro-5-nitro-pyrimidin-4-ylamino)-methyl]-cyclohexyl}-carbamic acid tert-butyl ester (200 mg, 0.52 mmol) was dissolved in CH2Cl2 (10 mL) and Et3N (0.289 mL, 2.07 mmol) was added. 3-Piperidin-1-yl-benzylamine (197 mg, 1.04 mmol) was dissolved in DMA:EtOH (2 mL, 1:1) and added to the reaction solution. The reaction was stirred at room temperature for 18 h. The volatiles were removed in vacuo and the crude was purified via flash chromatography (SiO2, 25-50% EtOAc:Hexanes then 5% MeOH:CH2Cl2) to afford 176 mg (63%) of (4-{[5-nitro-2-(3-piperidin-1-yl-benzylamino)-pyrimidin-4-ylamino]-methyl}-cyclohexyl)-carbamic acid tert-butyl ester
後処理
- customThe volatiles were removed in vacuo
- customthe crude was purified via flash chromatography (SiO2, 25-50% EtOAc
出典と根拠
- ORDレコード
- ord-cc85408cc8fa43c4b3e43322edef0a6a
- 出典データセット
- uspto-grants-2009_10
- 特許番号
- US07601714B2
反応ノート
読み込み中…